Please Wait.....
Report
Influenza Diagnostics Market - Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028)
Market Report I 2023-01-23 I 118 Pages I Mordor Intelligence
The global influenza diagnostics market is expected to grow at a CAGR of 6.9% during the forecast period (2022-2027).
COVID- 19 has significantly impacted the influenza diagnostics market due to the closing of manufacturing facilities due to lockdowns, unfavorable regulations and guidelines changes, and supply chain disruptions globally. Additionally, there are several similarities between COVID-19 and influenza, such as both are contagious viruses and show similar symptoms of respiratory illness. As COVID-19 affects a patient's respiratory system, it is necessary to diagnose influenza too for safety purposes. This has increased the testing for influenza during the pandemic.
The rising prevalence of influenza and related chronic diseases increased research funding for influenza diagnostics, and rising demand for early diagnosis and control of influenza are all factors driving the market growth. Influenza is recognized as a significant cause of morbidity and mortality in humans, prompting the development and implementation of diagnostics to reduce health and economic consequences. According to the updates from January 2022 by the Centers for Disease Control and Prevention, flu caused 9 million 41 million illnesses, 140,000-710,000 hospitalizations, and 12,000-52,000 deaths annually in the United States between 2010 and 2020.
Furthermore, according to the World Health Organization (WHO) updates from February 2021, during the years 2021-2022, WHO GISRS laboratories tested over 490 516 specimens. A total of 12 368 people tested positive for influenza viruses, with 8 423 (68.1%) being influenza A and 3 945 (31.9%) being influenza B. Various initiatives and research funding are assisting in the market's expansion. For example, the National Institute of Allergy and Infectious Diseases (NIAID) has funded a diverse range of influenza research, including studies that are helping to develop vaccines, diagnostics, and therapeutics for seasonal and pandemic influenza.
Moreover, in September 2021, DiaSorin Molecular LLC received a CE mark for its Simplexa COVID-19 & Flu A/B Direct kit. The multiplex test allows for the in vitro qualitative detection and differentiation of nucleic acid from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza A virus, and influenza B virus from the same patient sample in one reaction well. Also, in December 2021, Roche planned to launch the SARS-CoV-2 & Flu A/B Rapid Antigen Test for professional use in markets that accept CE Mark.
However, ensuring that all the rapid antigen flu tests meet new Food and Drug Administration (FDA) requirements for approval is critical. Hence, the stringent FDA regulations act as significant restraints for the market.
Influenza Diagnostics Market Trends
Rapid Influenza Diagnostic Test (RIDT) is Expected to hold its Highest Market Share in the Test Type Segment
In the test type segment of the influenza diagnostics market, among all traditional diagnostic tests, the rapid influenza diagnostic test (RIDT) is believed to have the largest market share in the studied market.
Rapid influenza diagnostic tests (RIDTs) are immunoassays that can detect influenza A and B viral nucleoprotein antigens in respiratory specimens and provide qualitative results. It can diagnose patients with influenza-like illness, especially if it is done within the first four days of symptoms appearing. The benefits of faster results and ease of use drive RIDT's popularity. Some RIDTs are also approved for use in the office or at the bedside. Because of their widespread use in point-of-care settings, the RIDT segment is also expected to increase.
However, because of its low to moderate sensitivities, one of the significant disadvantages of RIDT is that it produces false-negative results (50-70 percent ). When the novel H1N1 influenza epidemic struck in 2009, healthcare policymakers began to recognize the impact of its low sensitivity.
North America Dominates the Market and is Expected to do the Same in the Forecast Period
North America currently dominates the market for influenza diagnostics and is expected to continue its stronghold for a few more years.
The high prevalence of influenza is expected to drive the regional market over the forecast period. For instance, according to statistics published by MedAlertHelp, in 2022, about 5% to 20% of Americans will be diagnosed with influenza yearly. Further, according to the data published by the Centers for Disease Control and Prevention, in October 2021, 35 million flu-related illnesses, 380,000 flu-related hospitalizations, 20,000 flu-related deaths, and 16 million flu-related medical visits were reported in the 2019-2020 season. This growing disease burden is anticipated to impact market growth over the coming years positively.
As per data published by the Centers for Disease Control and Prevention (CDC) 2021, RIDTs are commonly available across the region. The reason behind the wide availability of the test is the reduced period needed to generate results. RIDT can yield results in 15 minutes. With increasing influenza-associated hospitalization and pediatric deaths and the interest of government organizations to better manage the disease, the North American influenza diagnostics market is expected to grow in the future.
Additionally, product launches by market players in the region are also driving the Influenza diagnostics market growth in the North American region. For instance, in September 2021, the American College of Obstetrics and Gynecology (ACOG) launched a new seasonal flu campaign: ACOG Fights Flu, to raise awareness about the diagnosis and the treatment of influenza, thereby boosting the market in the region.
Influenza Diagnostics Market Competitor Analysis
The influenza diagnostics market is highly competitive and consists of several significant players. In terms of market share, few major players currently dominate the market. Companies like Coris BioConcept, DiaSorin SpA, F. Hoffmann-La Roche AG, Meridian Bioscience Inc., Quidel Corporation, and Sekisui Diagnostics others, hold a substantial share in the market.
Additional Benefits:
The market estimate (ME) sheet in Excel format
3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Influenza
4.2.2 Growth in Research Funding for Influenza Diagnostics
4.2.3 Rising Demand for Early Diagnosis and Control of Influenza
4.3 Market Restraints
4.3.1 Rising Healthcare Costs Limiting the Usage of Novel Influenza Diagnostic Techniques?
4.3.2 Stringent Government Regulations
4.3.3 Variability in Sensitivity and Specificity among Influenza Diagnostic Tests?
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Test Type
5.1.1 Traditional Diagnostic Test
5.1.1.1 Rapid Influenza Diagnostic Test (RIDT)
5.1.1.2 Viral Culture
5.1.1.3 Direct Fluorescent Antibody (DFA) Test
5.1.1.4 Serological Assay
5.1.2 Molecular Diagnostic Assay
5.1.2.1 RT-PCR
5.1.2.2 Nucleic Acid Sequence-based Amplification (NASBA) Test
5.1.2.3 Loop-mediated Isothermal Amplification-based Assay (LAMP)
5.1.2.4 Simple Amplification-based Assay (SAMBA)
5.1.2.5 Other Molecular Diagnostic Assays
5.2 By End User
5.2.1 Hospital
5.2.2 Laboratories
5.2.3 Other End Users
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 Becton, Dickinson and Company
6.1.3 Coris BioConcept
6.1.4 DiaSorin SpA
6.1.5 F. Hoffmann-La Roche Ltd
6.1.6 Meridian Bioscience Inc.
6.1.7 Quidel Corporation
6.1.8 Sekisui Diagnostics
6.1.9 Thermo Fisher Scientific Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security